- Record Full Year Consolidated Net Income from Continuing Ops of
$21.0 Million or$0.19 Per Share, Adjusted EBITDA from Continuing Ops of$49.9 Million , and Operating Cash Flow of$58.1 Million - Consolidated Q4 Net Sales Increased 9% YoY to
$49.6 Million ; Canadian Cannabis Sales Increased 10% YoY; International Export Cannabis Sales Increased 384% YoY - Consolidated Q4 Net Income from Continuing Ops of
$2.3 Million or$0.02 Per Share, Adj. EBITDA from Continuing Ops of$8.6 Million , and Operating Cash Flow of$11.4 Million - Canadian Cannabis Delivers Q4 Gross Margin of 43%; Adj. EBITDA of
$9.8 Million or 25.8% of Sales - All Expansion Projects Remain on Time and Under Budget;
Delta 2 Expansion Commenced CultivationMarch 2 and Expected to Harvest 15 Tonnes of Incremental Capacity in 2026 - Netherlands Expansion on Track to Plant First Rooms in March with Full Facility Completion During Q2
- Company Ends 2025 with
$86 Million in Cash; Has Completed$6.7 Million of Share Repurchases since Q3
Management Commentary
“Our fourth quarter results again delivered strong profitability, gross margin and cash flow from operations which contributed to record levels of performance for each of these metrics in 2025,” said President and Chief Executive Officer
“We grew global cannabis sales by 17% year-over-year despite just a partial year of contributions from our expanding
“Demand for our products continues to significantly outpace our current production capacity, and temporary supply constraints coupled with rapidly evolving global regulatory frameworks has created near-term variability in performance as we balance the complex needs of our diverse customer base. In response to higher demand, we are pleased to report that last week we began cultivation in the first half of our previously-announced
“Our first
“We look to the remainder of 2026 with a growth mindset, and expect to maintain a balanced approach to capital allocation with prudent consideration of accretive organic and acquisitive investments and enhanced value creation for shareholders in the form of ongoing share repurchases. We believe our growth investments, strong net cash position, industry leading cost of capital, and continued solid execution from our teams position us for continued success in 2026 and beyond.”
Fourth Quarter 2025 Financial Highlights
(All comparable periods are for the fourth quarter of 2024 unless otherwise stated)
Consolidated
- Consolidated net sales increased 9% to
$49.6 million from$45.4 million ; - Consolidated net income from continuing operations improved to
$2.3 million , or$0.02 per share, from a net loss from continuing operations of$7.5 million , or ($0.04 ) per share driven by a$10.5 million non-cash impairment charge in the prior-year period related to non-flower inventory purchased primarily from third parties that did not meet the Company’s quality standards; - Consolidated net income, including non-controlling interests and before equity losses, was
$2.4 million , or$0.02 per share compared to net loss, including non-controlling interests and before equity losses, of$8.6 million , or ($0.07 ) per share; - Consolidated cash flow from continuing operations of
$11.4 million compared with$10.9 million in the prior year period; - Full year consolidated cash flow from continuing operations increased to
$58.1 million compared with$13.7 million in the prior-year period; and, - Consolidated adjusted EBITDA from continuing operations (a non-GAAP measure) was
$8.6 million or 17.3% of sales, compared with($2.9) million in the prior year period.
Canadian Cannabis
- Net sales increased 10% to
$37.8 million (C$52.7 million ) from$34.3 million (C$48.0 million ); - International export sales increased 384%; retail branded sales flat year-over-year in line with expectations;
- Gross margin increased to 43% from 2%, driven by improvements in operating efficiency leading to lower costs of production, an increased mix of higher-margin sales, and the non-recurrence of a non-cash inventory impairment charge in the prior-year quarter;
- Net income improved to
$5.4 million (C$7.5 million ) from negative$6.6 million (-C$9.4 million ); - Adjusted EBITDA increased to
$9.7 million (C$14.3 million ) from negative$6.3 million (-C$9.1 million ); and, - Cash flow from operations increased 752% to
$15.7 million (C$21.5 million ) from$2.6 million (C$3.3 million ).
- Net sales were
$3.4 million compared with$4.6 million ; - Gross margin decreased to 60% from 70%;
- Net loss was (
$0.2 million ) compared with a net loss of$0.2 million ; and - Adjusted EBITDA was (
$0.1 million ) compared with$0.3 million .
Netherlands Cannabis
Village Farms Netherlands was non-operational during the comparable quarter of 2024. As a result, comparative financial performance to the prior-year quarter is not meaningful.
- Net sales were
$3.3 million ; - Net loss was (
$0.1 million ) driven by increased operating expenses to support the Company’s Phase II expansion; and - Adjusted EBITDA was
$0.7 million .
Produce
- Sales from continuing operations of
$4.9 million were down from$6.1 million as compared to the prior year as 2025 sales are net of a commission paid toVanguard Food, L.P. , as well as lower year-over-year pricing; - Net loss from continuing operations was (
$1.6 million ) compared to net income from continuing operations of$4.9 million ; and, - Adjusted EBITDA from continuing operations was (
$462 thousand ) compared to adjusted EBITDA from continuing operations of$6.6 million which was the result of a legal settlement in the prior-year quarter.
Canadian Cannabis
- The Company continues to maintain a top five overall market share position in
Canada and held the number one position in dried flower as ofFebruary 2026 1 despite planned reductions in sales of lower-margin SKUs; - International export sales increased 384% year-over-year with demand from international customers continuing to meaningfully outpace current supply capabilities;
- We surpassed the high end of our targeted gross margin range of 30-40%, marking the fourth consecutive quarter meeting or exceeding the target range and contributing to record annual Adjusted EBITDA performance;
- Introduced several new and unique packaging innovations to the Canadian market, including the launch of a one-way aroma valve built directly into its dried flower packaging, windowed packaging for its flower products which enables consumers to see product before purchase, and a proprietary built-in matchbox accessory for its pre-roll offerings to meet growing demand for ready-to-enjoy cannabis experiences;
- Named the winner of Business Vancouver's (BIV) 2026 BC Export Awards in the Consumer Products category, recognizing our exceptional performance and contribution to
British Columbia's growing international trade economy; - Published groundbreaking peer-reviewed research in Scientific Reports (Nature Portfolio), highlighting the natural variability of THC potency within cannabis plants, reinforcing a need for a greater focus on product quality versus potency and more transparent and accurate labeling across the industry; and,
- During the fourth quarter, started the expansion of cultivation capacity in the remaining half of its
Delta 2 greenhouse to meet increasing demand in Canadian and our international export markets. Once completed and operating at full capacity, the expansion is expected to yield an incremental 40 tonnes of annualized cannabis production, expanding capacity by approximately 33% once completed.
1. Based on estimated retail sales from HiFyre, other third parties and provincial boards.
International
- International export sales increased 384% year-over-year, driven by continued strength of demand in
Germany and steady performance across other international markets; - We believe we remain the largest exporter of medical cannabis to
Europe , with three of the top five leading cultivars inGermany and four of the top 10 through our third-party distribution partners2; and - The Company expects to return to sequential growth in international medical export sales in Q1 of 2026.
2. Based on Company estimates and rankings compiled by German outlet Flowzz.
Netherlands Cannabis
- Operations at the Phase I facility in Drachten continue at full capacity, with continued strong margin performance and operating cash flow generation;
- The Company’s products are now represented in 96% of participating coffeeshops, representing increased market penetration of roughly 500 basis points sequentially from that of the third quarter;
- The Company continued to advance new product innovation in
the Netherlands market and subsequent to year end launched 10 new product offerings, including the first regulated blunt in market as well as infused spliffs and other pre-roll formats. It expects to continue launching new and innovative products in 2026; and - Construction of the Company’s Phase II facility in Groningen is nearing completion with the first grow rooms expected to be planted in late Q1 with full facility completion and planting expected in Q2. Once fully ramped, the Phase II facility is expected to quintuple total annualized production to approximately 10 tonnes.
- The Company believes it is poised to benefit from
President Trump's Executive Order to reschedule marijuana, which, if rescheduled, would represent a consequential step in modernizingU.S. cannabis policy and support the development of a regulatory framework more aligned with international drug policies. - The Company’s application for a
Texas medicinal marijuana license remains under review by theDepartment of Public Services ("DPS"). InDecember 2025 , nine new provisional licenses were awarded and DPS will award a minimum of three new awards on or beforeApril 1, 2026 . If awarded a license, the Company plans to work with its listing authority to structure an acceptable ownership structure and comply with all applicable regulatory requirements, which are still pending inTexas .
Corporate
Brian Stevenson was appointed to the newly created role of Global Chief Strategy Officer, where he is overseeing our enterprise-wide strategic agenda, including long-term growth strategy, global market assessment, and integration initiatives across regions and business units.Brian Ellis was appointed to the newly created role of Chief Information and Technology Officer (CITO), where he is overseeing our enterprise architecture and IT strategy as we continue executing our global growth strategy and transformation initiatives.- On
September 29, 2025 , the Company’s Board of Directors unanimously approved aUS$10 million share repurchase authorization for up to 5,687,000 common shares (five percent of our issued and outstanding common shares at the date of announcement). During the fourth quarter of 2025, the Company repurchased 812,923 shares at a cost of$3.0 million and subsequent to year end it has purchased 1,099,753 shares at a cost of$3.7 million . - Subsequent to year end, the Company amended and extended its Canadian cannabis credit facility by upsizing loan commitments with existing lenders by CAD
$15 million and extending maturities one year. The incremental financing comes in the form of a delayed draw term loan, from which the Company drew an initial CAD$5 million onFebruary 20, 2026 . All other terms of the credit facility loans remain unchanged, with variable interest rates currently below 6.0%.
Conference Call
Village Farms’ management team will host a conference call to discuss its fourth quarter and full year 2025 financial results today,
The live question and answer session will be limited to analysts; however, others are invited to submit questions ahead of the conference call via email at investorrelations@villagefarms.com. Management will address questions received via email during the question-and-answer session as time permits.
About
In
In
Contact Information
Senior Vice President,
Phone: (407) 936-1190 ext. 328
Email: sgibbons@villagefarms.com
Phone: (416) 519-4196
Email: lawrence.chamberlain@loderockadvisors.com
Canadian Cannabis Performance Summary
| (millions except % metrics) | Three Months Ended | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| CAD $ | USD $ | CAD $ | USD $ | Change of C $ | |||||||||||||
| Total | $ | 52.7 | $ | 37.8 | $ | 48.0 | $ | 34.3 | 10% | ||||||||
| Total Cost of Sales | $ | 30.0 | $ | 22.2 | $ | 47.0 | $ | 33.4 | -36% | ||||||||
| Gross Profit | $ | 22.7 | $ | 15.8 | $ | 1.0 | $ | 0.9 | 2170% | ||||||||
| Gross Margin % | 43% | 42% | 2% | 3% | 1968% | ||||||||||||
| SG&A | $ | 11.6 | $ | 8.4 | $ | 13.4 | $ | 9.6 | -13% | ||||||||
| Net income (loss) | $ | 7.5 | $ | 5.4 | $ | (9.4 | ) | $ | (6.6 | ) | NM | ||||||
| Adjusted EBITDA from Cont. Ops.(1) | $ | 14.3 | $ | 9.7 | $ | (9.1 | ) | $ | (6.3 | ) | NM | ||||||
| Adjusted EBITDA Margin from Cont. Ops.(1) | 27% | 26% | -19% | -18% | NM | ||||||||||||
| Cash flow from Operations | $ | 21.5 | $ | 15.6 | $ | (3.3 | ) | $ | (2.6 | ) | NM | ||||||
| (millions except % metrics) | Year Ended | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| CAD $ | USD $ | CAD $ | USD $ | Change of C $ | |||||||||||||
| Total | $ | 228.2 | $ | 163.7 | $ | 204.0 | $ | 148.9 | 12% | ||||||||
| Total Cost of Sales | $ | 127.7 | $ | 92.2 | $ | 162.4 | $ | 118.2 | -21% | ||||||||
| Gross Profit | $ | 100.5 | $ | 71.5 | $ | 41.6 | $ | 30.7 | 142% | ||||||||
| Gross Margin % | 44% | 44% | 20% | 21% | 116% | ||||||||||||
| SG&A | $ | 48.7 | $ | 34.9 | $ | 46.7 | $ | 34.0 | 4% | ||||||||
| Net income (loss) | $ | 37.0 | $ | 26.6 | $ | (4.8 | ) | $ | (3.2 | ) | NM | ||||||
| Adjusted EBITDA from Cont. Ops.(1) | $ | 67.0 | $ | 47.6 | $ | 9.4 | $ | 7.3 | 613% | ||||||||
| Adjusted EBITDA Margin from Cont. Ops.(1) | 29% | 29% | 5% | 5% | 537% | ||||||||||||
| Cash flow from Operations | $ | 77.5 | $ | 56.2 | $ | 16.1 | $ | 11.7 | 381% | ||||||||
Canadian Cannabis’ Composition of Sales by Channel
| (millions except % metrics) | Three Months Ended | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| CAD $ | USD $ | CAD $ | USD $ | Change of C $ | |||||||||||||
| Retail Branded Sales | $ | 55.6 | $ | 39.9 | $ | 55.8 | $ | 39.9 | 0% | ||||||||
| Non-Branded Sales | $ | 5.7 | $ | 4.2 | $ | 9.5 | $ | 6.9 | -40% | ||||||||
| International Sales | $ | 12.1 | $ | 8.7 | $ | 2.5 | $ | 1.7 | 384% | ||||||||
| Other | $ | 0.8 | $ | 0.5 | $ | 0.9 | $ | 0.6 | -11% | ||||||||
| Less: Excise Taxes | $ | (21.5 | ) | $ | (15.3 | ) | $ | (20.7 | ) | $ | (14.8 | ) | 4% | ||||
| $ | 52.7 | $ | 37.8 | $ | 48.0 | $ | 34.3 | 10% | |||||||||
| (millions except % metrics) | Year Ended | ||||||||||||||||
| 2025 | 2024 | ||||||||||||||||
| CAD $ | USD $ | CAD $ | USD $ | Change of C $ | |||||||||||||
| Retail Branded Sales | $ | 221.9 | $ | 158.9 | $ | 251.7 | $ | 183.9 | -12% | ||||||||
| Non-Branded Sales | $ | 34.5 | $ | 25.0 | $ | 39.6 | $ | 28.9 | -13% | ||||||||
| International Sales | $ | 52.7 | $ | 37.9 | $ | 8.4 | $ | 6.1 | 527% | ||||||||
| Other | $ | 2.8 | $ | 2.0 | $ | 2.7 | $ | 1.9 | 4% | ||||||||
| Less: Excise Taxes | $ | (83.7 | ) | $ | (60.0 | ) | $ | (98.4 | ) | $ | (72.0 | ) | -15% | ||||
| $ | 228.2 | $ | 163.9 | $ | 204.0 | $ | 148.9 | 12% | |||||||||
Presentation of Financial Results
The Company’s financial statements for the three months and year ended
RESULTS OF OPERATIONS
(In thousands of
| Three Months Ended | Year Ended | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Sales | $ | 49,617 | $ | 45,385 | $ | 215,937 | $ | 195,907 | |||||||
| Cost of sales | (30,395 | ) | (39,886 | ) | (128,255 | ) | (150,106 | ) | |||||||
| Gross margin | 19,222 | 7,310 | 87,682 | 45,801 | |||||||||||
| Selling, general and administrative expenses | (14,664 | ) | (15,877 | ) | (60,293 | ) | (61,748 | ) | |||||||
| Interest expense | (542 | ) | (771 | ) | (2,704 | ) | (3,365 | ) | |||||||
| Interest income | 619 | 157 | 1,163 | 914 | |||||||||||
| Foreign exchange (loss) gain | 85 | (1,914 | ) | 1,555 | (2,843 | ) | |||||||||
| Other income (expense) | 4 | 3,487 | 4,173 | 4,015 | |||||||||||
| — | — | — | (11,939 | ) | |||||||||||
| Other impairments | (217 | ) | (439 | ) | (217 | ) | (439 | ) | |||||||
| Loss before taxes and loss from equity method investments | 4,507 | (8,047 | ) | 31,359 | (29,604 | ) | |||||||||
| Provision for income taxes | (2,168 | ) | 2,336 | (10,371 | ) | 1,662 | |||||||||
| Loss from equity method investments | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 2,339 | (5,711 | ) | 20,988 | (27,942 | ) | |||||||||
| Income (loss) from discontinued operations, net of tax | 102 | (1,135 | ) | 11,117 | (7,702 | ) | |||||||||
| Income (loss) including non-controlling interests and before equity losses | 2,441 | (8,657 | ) | 32,105 | (35,644 | ) | |||||||||
| Less: net loss (income) attributable to non-controlling interests, net of tax | (11 | ) | 27 | 336 | (207 | ) | |||||||||
| Net loss attributable to | 2,430 | (8,630 | ) | 32,441 | (35,851 | ) | |||||||||
| Adjusted EBITDA from continuing operations(1) | 8,606 | (2,942 | ) | 49,852 | 7,374 | ||||||||||
| Basic income (loss) per share attributable to | |||||||||||||||
| Continuing operations | $ | 0.02 | $ | (0.05 | ) | $ | 0.19 | $ | (0.25 | ) | |||||
| Discontinued operations | 0.00 | (0.03 | ) | 0.10 | (0.07 | ) | |||||||||
| Basic income (loss) per share attributable to | $ | 0.02 | $ | (0.07 | ) | $ | 0.29 | $ | (0.32 | ) | |||||
| Diluted income (loss) per share attributable to | |||||||||||||||
| Continuing operations | $ | 0.02 | $ | (0.04 | ) | $ | 0.18 | $ | (0.25 | ) | |||||
| Discontinued operations | (0.01 | ) | (0.03 | ) | 0.09 | (0.07 | ) | ||||||||
| Diluted income (loss) per share attributable to | $ | 0.01 | $ | (0.07 | ) | $ | 0.27 | $ | (0.32 | ) | |||||
(1) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 70% interest in Rose LifeScience through
We caution that our results of operations for the three months and twelve months ended
SEGMENTED RESULTS OF OPERATIONS
(In thousands of
| For the Three Months Ended | |||||||||||||||||||||||||||
| Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | |||||||||||||||||||||
| Sales | $ | 4,853 | $ | 37,772 | $ | 3,357 | $ | 333 | $ | 3,302 | $ | — | $ | 49,617 | |||||||||||||
| Cost of sales | (5,161 | ) | (22,132 | ) | (1,352 | ) | (55 | ) | (1,695 | ) | — | (30,395 | ) | ||||||||||||||
| Selling, general and administrative expenses | (990 | ) | (8,366 | ) | (2,180 | ) | (25 | ) | (1,151 | ) | (1,952 | ) | (14,664 | ) | |||||||||||||
| Other (expense) income, net | (246 | ) | (243 | ) | — | — | (64 | ) | 502 | (51 | ) | ||||||||||||||||
| Other impairments | — | — | — | — | — | — | — | ||||||||||||||||||||
| Income (loss) before taxes and equity method investment income | (1,544 | ) | 7,031 | (175 | ) | 253 | 392 | (1,450 | ) | 4,507 | |||||||||||||||||
| Provision for income taxes | (31 | ) | (1,642 | ) | — | — | (495 | ) | — | (2,168 | ) | ||||||||||||||||
| Equity method investment income, net of tax | — | — | — | — | — | — | — | ||||||||||||||||||||
| Income (loss) from continuing operations | (1,575 | ) | 5,389 | (175 | ) | 253 | (103 | ) | (1,450 | ) | 2,339 | ||||||||||||||||
| Loss from discontinued operations net of tax | 102 | — | — | — | — | — | 102 | ||||||||||||||||||||
| Income (loss) including non-controlling interests | (1,473 | ) | 5,389 | (175 | ) | 253 | (103 | ) | (1,450 | ) | 2,441 | ||||||||||||||||
| Less: net income attributable to non-controlling interests, net of tax | — | (11 | ) | — | — | — | — | (11 | ) | ||||||||||||||||||
| Net income (loss) | $ | (1,473 | ) | $ | 5,378 | $ | (175 | ) | $ | 253 | $ | (103 | ) | $ | (1,450 | ) | $ | 2,430 | |||||||||
| Adjusted EBITDA from continuing operations(1) | $ | (462 | ) | $ | 9,755 | $ | (115 | ) | $ | 253 | $ | 739 | $ | (1,564 | ) | $ | 8,606 | ||||||||||
| Basic income (loss) per share from continuing operations | (0.01 | ) | 0.04 | 0.01 | (0.01 | ) | 0.00 | (0.01 | ) | 0.02 | |||||||||||||||||
| Basic income per share from discontinued operations | — | — | — | — | — | — | — | ||||||||||||||||||||
| Basic income (loss) per share | $ | (0.01 | ) | $ | 0.04 | $ | 0.01 | $ | (0.01 | ) | $ | 0.00 | $ | (0.01 | ) | $ | 0.02 | ||||||||||
| Diluted income (loss) per share from continuing operations | $ | (0.01 | ) | $ | 0.04 | $ | 0.00 | $ | (0.01 | ) | $ | 0.00 | $ | (0.01 | ) | 0.02 | |||||||||||
| Diluted income per share from discontinued operations | (0.01 | ) | - | - | - | - | - | (0.01 | ) | ||||||||||||||||||
| Diluted income (loss) per share | $ | (0.02 | ) | $ | 0.04 | $ | 0.00 | $ | (0.01 | ) | $ | 0.00 | $ | (0.01 | ) | $ | 0.01 | ||||||||||
| For the Three Months Ended | |||||||||||||||||||||||||||
| Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | |||||||||||||||||||||
| Sales | $ | 6,131 | $ | 34,202 | $ | 4,613 | $ | 439 | $ | — | $ | — | $ | 45,385 | |||||||||||||
| Cost of sales | (5,132 | ) | (33,330 | ) | (1,402 | ) | (22 | ) | — | — | (39,886 | ) | |||||||||||||||
| Selling, general and administrative expenses | (675 | ) | (9,592 | ) | (2,932 | ) | — | (466 | ) | (2,212 | ) | (15,877 | ) | ||||||||||||||
| Other expense, net | 2,814 | (320 | ) | — | — | — | (1,535 | ) | 959 | ||||||||||||||||||
| — | — | — | — | — | — | — | |||||||||||||||||||||
| Other impairments | — | — | (439 | ) | — | — | — | (439 | ) | ||||||||||||||||||
| Income (loss) before taxes and equity method investment income | 3,138 | (9,040 | ) | (160 | ) | 417 | (466 | ) | (3,747 | ) | (9,858 | ) | |||||||||||||||
| (Provision for) recovery of income taxes | (77 | ) | 2,433 | — | — | 152 | (172 | ) | 2,336 | ||||||||||||||||||
| Equity method investment income, net of tax | — | — | — | — | — | — | — | ||||||||||||||||||||
| Income (loss) from continuing operations | 3,061 | (6,607 | ) | (160 | ) | 417 | (314 | ) | (3,919 | ) | (7,522 | ) | |||||||||||||||
| Income from discontinued operations net of tax | (1,135 | ) | — | — | — | — | — | (1,135 | ) | ||||||||||||||||||
| Income (loss) including non-controlling interests | 1,926 | (6,607 | ) | (160 | ) | 417 | (314 | ) | (3,919 | ) | (8,657 | ) | |||||||||||||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | — | 27 | — | — | — | — | 27 | ||||||||||||||||||||
| Net income (loss) | $ | 1,926 | $ | (6,580 | ) | $ | (160 | ) | $ | 417 | $ | (314 | ) | $ | (3,919 | ) | $ | (8,630 | ) | ||||||||
| Adjusted EBITDA from continuing operations(1) | $ | 4,751 | $ | (6,361 | ) | $ | 342 | $ | 417 | $ | (140 | ) | $ | (1,951 | ) | $ | (2,942 | ) | |||||||||
| Basic income (loss) per share from continuing operations | $ | 0.05 | $ | (0.06 | ) | $ | 0.00 | $ | 0.01 | $ | 0.00 | $ | (0.04 | ) | $ | (0.04 | ) | ||||||||||
| Basic income per share from discontinued operations | (0.03 | ) | - | - | - | - | - | (0.03 | ) | ||||||||||||||||||
| Basic income (loss) per share | $ | 0.02 | $ | (0.06 | ) | $ | 0.00 | $ | 0.01 | $ | 0.00 | $ | (0.04 | ) | $ | (0.07 | ) | ||||||||||
| Diluted income (loss) per share from continuing operations | $ | 0.05 | $ | (0.06 | ) | $ | 0.00 | $ | 0.01 | $ | (0.00 | ) | $ | (0.04 | ) | $ | (0.04 | ) | |||||||||
| Diluted income per share from discontinued operations | (0.03 | ) | (0.00 | ) | - | - | 0.00 | - | (0.03 | ) | |||||||||||||||||
| Diluted income (loss) per share | $ | 0.02 | $ | (0.06 | ) | $ | 0.00 | $ | 0.01 | $ | 0.00 | $ | (0.04 | ) | $ | (0.07 | ) | ||||||||||
| For the Year Ended | |||||||||||||||||||||||||||
| Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | |||||||||||||||||||||
| Sales | $ | 26,295 | $ | 163,710 | $ | 14,439 | $ | 1,635 | $ | 9,858 | $ | — | $ | 215,937 | |||||||||||||
| Cost of sales | (25,438 | ) | (92,172 | ) | (5,416 | ) | (274 | ) | (4,955 | ) | — | (128,255 | ) | ||||||||||||||
| Selling, general and administrative expenses | (2,792 | ) | (34,872 | ) | (9,585 | ) | (48 | ) | (2,849 | ) | (10,147 | ) | (60,293 | ) | |||||||||||||
| Other (expense) income, net | 3,232 | (1,063 | ) | (3 | ) | — | (108 | ) | 2,129 | 4,187 | |||||||||||||||||
| Other impairments | — | — | (217 | ) | — | — | — | (217 | ) | ||||||||||||||||||
| Income (loss) before taxes and equity method investment income | 1,297 | 35,603 | (565 | ) | 1,313 | 1,946 | (8,018 | ) | 31,576 | ||||||||||||||||||
| Provision for income taxes | (57 | ) | (9,362 | ) | — | (286 | ) | (666 | ) | — | (10,371 | ) | |||||||||||||||
| Equity method investment income, net of tax | — | — | — | — | — | — | — | ||||||||||||||||||||
| Income (loss) from continuing operations | 1,240 | 26,241 | (782 | ) | 1,027 | 1,280 | (8,018 | ) | 20,988 | ||||||||||||||||||
| Loss from discontinued operations net of tax | 11,117 | — | — | — | — | — | 11,117 | ||||||||||||||||||||
| Income (loss) including non-controlling interests | 12,357 | 26,241 | (782 | ) | 1,027 | 1,280 | (8,018 | ) | 32,105 | ||||||||||||||||||
| Less: net income attributable to non-controlling interests, net of tax | — | 336 | — | — | — | — | 336 | ||||||||||||||||||||
| Net income (loss) | $ | 12,357 | $ | 26,577 | $ | (782 | ) | $ | 1,027 | $ | 1,280 | $ | (8,018 | ) | $ | 32,441 | |||||||||||
| Adjusted EBITDA from continuing operations(1) | $ | 6,666 | $ | 47,623 | $ | (288 | ) | $ | 1,313 | $ | 3,299 | $ | (8,761 | ) | $ | 49,852 | |||||||||||
| Basic income (loss) per share from continuing operations | $ | 0.01 | $ | 0.23 | $ | — | $ | 0.01 | $ | 0.01 | $ | (0.07 | ) | $ | 0.19 | ||||||||||||
| Basic income per share from discontinued operations | 0.10 | — | — | — | — | — | 0.10 | ||||||||||||||||||||
| Basic income (loss) per share | $ | 0.11 | $ | 0.23 | $ | — | $ | 0.01 | $ | 0.01 | $ | (0.07 | ) | $ | 0.29 | ||||||||||||
| Diluted income (loss) per share from continuing operations | $ | 0.01 | $ | 0.22 | $ | (0.01 | ) | $ | 0.01 | $ | 0.01 | $ | (0.07 | ) | $ | 0.18 | |||||||||||
| Diluted income per share from discontinued operations | 0.09 | - | - | - | - | - | 0.09 | ||||||||||||||||||||
| Diluted income (loss) per share | $ | 0.10 | $ | 0.22 | $ | (0.01 | ) | $ | 0.01 | $ | 0.01 | $ | (0.07 | ) | $ | 0.27 | |||||||||||
| For the Year Ended | |||||||||||||||||||||||||||
| Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | |||||||||||||||||||||
| Sales | $ | 28,909 | $ | 148,856 | $ | 17,390 | $ | 752 | $ | — | $ | — | $ | 195,907 | |||||||||||||
| Cost of sales | (25,450 | ) | (118,172 | ) | (6,355 | ) | (129 | ) | — | — | (150,106 | ) | |||||||||||||||
| Selling, general and administrative expenses | (2,949 | ) | (34,028 | ) | (11,990 | ) | (38 | ) | (1,555 | ) | (11,188 | ) | (61,748 | ) | |||||||||||||
| Other expense, net | 1,408 | (1,007 | ) | — | 170 | — | (1,850 | ) | (1,279 | ) | |||||||||||||||||
| — | — | (11,939 | ) | — | — | — | (11,939 | ) | |||||||||||||||||||
| Other impairments | — | — | (439 | ) | — | — | — | (439 | ) | ||||||||||||||||||
| Income (loss) before taxes and equity method investment income | 1,918 | (4,351 | ) | (13,333 | ) | 755 | (1,555 | ) | (13,038 | ) | (29,604 | ) | |||||||||||||||
| (Provision for) recovery of income taxes | (100 | ) | 1,537 | — | — | 391 | (166 | ) | 1,662 | ||||||||||||||||||
| Equity method investment income, net of tax | — | — | — | — | — | — | — | ||||||||||||||||||||
| Income (loss) from continuing operations | 1,818 | (2,814 | ) | (13,333 | ) | 755 | (1,164 | ) | (13,204 | ) | (27,942 | ) | |||||||||||||||
| Income from discontinued operations net of tax | (7,702 | ) | — | — | — | — | — | (7,702 | ) | ||||||||||||||||||
| Income (loss) including non-controlling interests | (5,884 | ) | (2,814 | ) | (13,333 | ) | 755 | (1,164 | ) | (13,204 | ) | (35,644 | ) | ||||||||||||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | — | (367 | ) | — | — | 160 | — | (207 | ) | ||||||||||||||||||
| Net income (loss) | $ | (5,884 | ) | $ | (3,181 | ) | $ | (13,333 | ) | $ | 755 | $ | (1,004 | ) | $ | (13,204 | ) | $ | (35,851 | ) | |||||||
| Adjusted EBITDA from continuing operations(1) | $ | 7,742 | $ | 7,282 | $ | (672 | ) | $ | 771 | $ | (259 | ) | $ | (7,490 | ) | $ | 7,374 | ||||||||||
| Basic income (loss) per share from continuing operations | $ | 0.02 | $ | (0.03 | ) | $ | (0.12 | ) | $ | 0.01 | $ | (0.01 | ) | $ | (0.12 | ) | $ | (0.25 | ) | ||||||||
| Basic income per share from discontinued operations | (0.07 | ) | — | — | — | — | — | (0.07 | ) | ||||||||||||||||||
| Basic income (loss) per share | $ | (0.05 | ) | $ | (0.03 | ) | $ | (0.12 | ) | $ | 0.01 | $ | (0.01 | ) | $ | (0.12 | ) | $ | (0.32 | ) | |||||||
| Diluted income (loss) per share from continuing operations | $ | 0.02 | $ | (0.03 | ) | $ | (0.12 | ) | $ | 0.01 | $ | (0.01 | ) | $ | (0.12 | ) | $ | (0.25 | ) | ||||||||
| Diluted income per share from discontinued operations | (0.07 | ) | (0.00 | ) | - | - | 0.00 | - | (0.07 | ) | |||||||||||||||||
| Diluted income (loss) per share | $ | (0.05 | ) | $ | (0.03 | ) | $ | (0.12 | ) | $ | 0.01 | $ | (0.01 | ) | $ | (0.12 | ) | $ | (0.32 | ) | |||||||
(1) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company.
Reconciliation of Net Income (Loss) to Adjusted EBITDA
The following tables reflect a reconciliation of net income (loss) from continuing operations to Adjusted EBITDA from continuing operations, as presented by the Company:
| For the Three Months Ended | |||||||||||||||||||||||||||
| (in thousands of | Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | ||||||||||||||||||||
| Net income (loss) from continuing operations | $ | (1,575 | ) | $ | 5,389 | $ | (175 | ) | $ | 253 | $ | (103 | ) | $ | (1,450 | ) | $ | 2,339 | |||||||||
| Add: | |||||||||||||||||||||||||||
| Amortization and depreciation | 795 | 2,595 | 47 | — | 348 | 22 | 3,807 | ||||||||||||||||||||
| Foreign currency exchange loss | (38 | ) | 16 | — | — | (1 | ) | (117 | ) | (140 | ) | ||||||||||||||||
| Interest expense (income), net | 237 | 73 | — | — | (2 | ) | (385 | ) | (77 | ) | |||||||||||||||||
| Provision for (recovery of) income taxes | 30 | 1,643 | — | — | 495 | — | 2,168 | ||||||||||||||||||||
| Share-based compensation | (8 | ) | 90 | 9 | — | 2 | 366 | 459 | |||||||||||||||||||
| Deferred financing fees | — | 37 | — | — | — | — | 37 | ||||||||||||||||||||
| Other impairments | — | — | — | — | — | — | — | ||||||||||||||||||||
| Other expense, net | 97 | — | 4 | — | — | — | 101 | ||||||||||||||||||||
| Adjustments attributable to non-controlling interest | — | (88 | ) | — | — | — | — | (88 | ) | ||||||||||||||||||
| Adjusted EBITDA from continuing operations(2) | $ | (462 | ) | $ | 9,755 | $ | (115 | ) | $ | 253 | $ | 739 | $ | (1,564 | ) | $ | 8,606 | ||||||||||
| For the Three Months Ended | |||||||||||||||||||||||||||
| (in thousands of | Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | ||||||||||||||||||||
| Net income (loss) from continuing operations | $ | 3,061 | $ | (6,607 | ) | $ | (160 | ) | $ | 417 | $ | (314 | ) | $ | (3,919 | ) | $ | (7,522 | ) | ||||||||
| Add: | |||||||||||||||||||||||||||
| Amortization and depreciation | 802 | 2,569 | 50 | — | 324 | 44 | 3,789 | ||||||||||||||||||||
| Foreign currency exchange (gain) loss | 259 | 48 | — | — | — | 1,562 | 1,869 | ||||||||||||||||||||
| Interest expense (income), net | 535 | 105 | — | — | — | (26 | ) | 614 | |||||||||||||||||||
| Provision for (recovery of) income taxes | 77 | (2,433 | ) | — | — | (150 | ) | 170 | (2,336 | ) | |||||||||||||||||
| Share-based compensation | — | 40 | 13 | — | — | 218 | 271 | ||||||||||||||||||||
| Deferred financing fees | — | — | — | — | — | — | — | ||||||||||||||||||||
| — | — | — | — | — | — | — | |||||||||||||||||||||
| Other impairments | — | — | 439 | — | — | — | 439 | ||||||||||||||||||||
| Other expense | 17 | — | — | — | — | — | 17 | ||||||||||||||||||||
| Adjustments attributable to non-controlling interest | — | (83 | ) | — | — | — | — | (83 | ) | ||||||||||||||||||
| Adjusted EBITDA from continuing operations(2) | $ | 4,751 | $ | (6,361 | ) | $ | 342 | $ | 417 | $ | (140 | ) | $ | (1,951 | ) | $ | (2,942 | ) | |||||||||
| For the Year Ended | |||||||||||||||||||||||||||
| (in thousands of | Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | ||||||||||||||||||||
| Net income (loss) from continuing operations | $ | 1,240 | $ | 26,241 | $ | (782 | ) | $ | 1,027 | $ | 1,280 | $ | (8,018 | ) | $ | 20,988 | |||||||||||
| Add: | |||||||||||||||||||||||||||
| Amortization and depreciation | 3,881 | 10,826 | 192 | — | 1,351 | 129 | 16,379 | ||||||||||||||||||||
| Foreign currency exchange loss | (132 | ) | (100 | ) | — | — | (1 | ) | (1,444 | ) | (1,677 | ) | |||||||||||||||
| Interest expense (income), net | 1,506 | 722 | — | — | (2 | ) | (685 | ) | 1,541 | ||||||||||||||||||
| Provision for (recovery of) income taxes | 56 | 9,363 | — | 286 | 666 | — | 10,371 | ||||||||||||||||||||
| Share-based compensation | 18 | 380 | 81 | — | 5 | 1,257 | 1,741 | ||||||||||||||||||||
| Deferred financing fees | — | 116 | — | — | — | — | 116 | ||||||||||||||||||||
| Other impairments | — | — | 217 | — | — | — | 217 | ||||||||||||||||||||
| Other expense, net | 97 | — | 4 | — | — | — | 101 | ||||||||||||||||||||
| Adjustments attributable to non-controlling interest | — | 75 | — | — | — | — | 75 | ||||||||||||||||||||
| Adjusted EBITDA from continuing operations(2) | $ | 6,666 | $ | 47,623 | $ | (288 | ) | $ | 1,313 | $ | 3,299 | $ | (8,761 | ) | $ | 49,852 | |||||||||||
| For the Year Ended | |||||||||||||||||||||||||||
| (in thousands of | Produce | Cannabis | Cannabis | Clean Energy | Cannabis | Corporate | Total | ||||||||||||||||||||
| Net income (loss) from continuing operations | $ | 1,818 | $ | (2,814 | ) | $ | (13,333 | ) | $ | 755 | $ | (1,164 | ) | $ | (13,204 | ) | $ | (27,942 | ) | ||||||||
| Add: | |||||||||||||||||||||||||||
| Amortization and depreciation | 3,258 | 11,790 | 204 | — | 1,275 | 196 | 16,723 | ||||||||||||||||||||
| Foreign currency exchange (gain) loss | 317 | 42 | — | — | — | 2,276 | 2,635 | ||||||||||||||||||||
| Interest expense (income), net | 2,232 | 629 | — | 16 | — | (426 | ) | 2,451 | |||||||||||||||||||
| Provision for (recovery of) income taxes | 100 | (1,537 | ) | — | — | (391 | ) | 166 | (1,662 | ) | |||||||||||||||||
| Share-based compensation | — | 166 | 79 | — | — | 3,502 | 3,747 | ||||||||||||||||||||
| Deferred financing fees | — | 10 | — | — | — | — | 10 | ||||||||||||||||||||
| — | — | 11,939 | — | — | — | 11,939 | |||||||||||||||||||||
| Other impairments | — | — | 439 | — | — | — | 439 | ||||||||||||||||||||
| Other expense | 17 | — | — | — | — | — | 17 | ||||||||||||||||||||
| Adjustments attributable to non-controlling interest | — | (1,004 | ) | — | — | 21 | — | (983 | ) | ||||||||||||||||||
| Adjusted EBITDA from continuing operations(2) | $ | 7,742 | $ | 7,282 | $ | (672 | ) | $ | 771 | $ | (259 | ) | $ | (7,490 | ) | $ | 7,374 | ||||||||||
(2) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company.
(3) Reflects impairment to goodwill and intangibles of
This press release is intended to be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended
Cautionary Statement Regarding Forward-Looking Information
As used in this Press Release, the terms “Village Farms”, “Village Farms International”, the “Company”, “we”, “us”, “our” and similar references refer to
This Press Release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the
The Company has based these forward-looking statements on factors and assumptions about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Although the forward-looking statements contained in this Press Release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Company's control, which may cause the Company's or the industry's actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company's filings with securities regulators, including this Press Release and the Annual Report.
When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this Press Release relate only to events or information as of the date on which the statements are made in this Press Release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Consolidated Statements of Financial Position (In thousands of (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 81,189 | $ | 24,631 | ||||
| Restricted cash | 5,063 | — | ||||||
| Trade receivables, net | 23,151 | 22,160 | ||||||
| Inventories, net | 41,519 | 41,256 | ||||||
| Other receivables | 324 | 247 | ||||||
| Prepaid expenses and deposits | 3,191 | 2,806 | ||||||
| Current assets of discontinued operations (Note 10) | — | 24,919 | ||||||
| Total current assets | 154,437 | 116,019 | ||||||
| Non-current assets | ||||||||
| Property, plant and equipment, net | 185,712 | 175,226 | ||||||
| Investments | 6,276 | 2,656 | ||||||
| 44,365 | 42,315 | |||||||
| Intangibles, net | 23,647 | 25,105 | ||||||
| Deferred tax asset | 694 | 1,005 | ||||||
| Right-of-use assets | 4,066 | 4,372 | ||||||
| Other assets | 3,899 | 2,178 | ||||||
| Non-current assets of discontinued operations (Note 10) | — | 20,430 | ||||||
| Total assets | $ | 423,096 | $ | 389,306 | ||||
| LIABILITIES | ||||||||
| Current liabilities | ||||||||
| Line of credit | $ | — | $ | 4,000 | ||||
| Trade payables | 15,748 | 11,254 | ||||||
| Current maturities of long-term debt | 4,885 | 8,142 | ||||||
| Accrued sales taxes | 8,695 | 8,740 | ||||||
| Accrued loyalty program | 541 | 1,029 | ||||||
| Accrued liabilities | 13,419 | 8,972 | ||||||
| Lease liabilities - current | 1,198 | 1,060 | ||||||
| Income tax payable | 12,151 | 51 | ||||||
| Other current liabilities | 1,950 | 1,053 | ||||||
| Current liabilities of discontinued operations (Note 10) | — | 17,918 | ||||||
| Total current liabilities | 58,587 | 62,219 | ||||||
| Non-current liabilities | ||||||||
| Long-term debt | 28,769 | 32,420 | ||||||
| Deferred tax liability | 18,494 | 19,940 | ||||||
| Lease liabilities - non-current | 3,855 | 4,199 | ||||||
| Other liabilities | 3,330 | 2,196 | ||||||
| Non-current liabilities of discontinued operations (Note 10) | — | 4,374 | ||||||
| Total liabilities | 113,035 | 125,348 | ||||||
| Commitments and contingencies (Note 12) | ||||||||
| MEZZANINE EQUITY | ||||||||
| Redeemable non-controlling interests | 10,163 | 9,953 | ||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Common stock, no par value per share - unlimited shares authorized; 115,722,312 shares issued and outstanding at | 392,380 | 387,349 | ||||||
| Additional paid in capital | 29,374 | 30,604 | ||||||
| Accumulated other comprehensive loss | (9,281 | ) | (18,932 | ) | ||||
| Retained earnings | (112,575 | ) | (145,016 | ) | ||||
| Total shareholders' equity | 299,898 | 254,005 | ||||||
| Total liabilities, mezzanine equity and shareholders’ equity | $ | 423,096 | $ | 389,306 | ||||
Consolidated Statements of Operations and Comprehensive Income (Loss) (In thousands of (Unaudited) | |||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Sales | $ | 49,617 | $ | 45,385 | $ | 215,937 | $ | 195,907 | |||||||
| Cost of sales | (30,395 | ) | (39,886 | ) | (128,255 | ) | (150,106 | ) | |||||||
| Gross margin | 19,222 | 7,310 | 87,682 | 45,801 | |||||||||||
| Selling, general and administrative expenses | (14,664 | ) | (15,877 | ) | (60,293 | ) | (61,748 | ) | |||||||
| Interest expense | (542 | ) | (771 | ) | (2,704 | ) | (3,365 | ) | |||||||
| Interest income | 619 | 157 | 1,163 | 914 | |||||||||||
| Foreign exchange (loss) gain | 85 | (1,914 | ) | 1,555 | (2,843 | ) | |||||||||
| Other income (expense) | 4 | 3,487 | 4,173 | 4,015 | |||||||||||
| — | — | — | (11,939 | ) | |||||||||||
| Other impairments | (217 | ) | (439 | ) | (217 | ) | (439 | ) | |||||||
| Loss before taxes and loss from equity method investments | 4,507 | (8,047 | ) | 31,359 | (29,604 | ) | |||||||||
| Provision for income taxes | (2,168 | ) | 2,336 | (10,371 | ) | 1,662 | |||||||||
| Loss from equity method investments | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 2,339 | (5,711 | ) | 20,988 | (27,942 | ) | |||||||||
| Income (loss) from discontinued operations, net of tax | 102 | (1,135 | ) | 11,117 | (7,702 | ) | |||||||||
| Loss including non-controlling interests and before equity losses | 2,441 | (8,657 | ) | 32,105 | (35,644 | ) | |||||||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | (11 | ) | 27 | 336 | (207 | ) | |||||||||
| Net loss attributable to | 2,430 | (8,630 | ) | 32,441 | (35,851 | ) | |||||||||
| Adjusted EBITDA from continuing operations | 8,606 | (2,942 | ) | 49,852 | 7,374 | ||||||||||
| Basic income (loss) per share attributable to | |||||||||||||||
| Continuing operations | $ | 0.02 | $ | (0.05 | ) | $ | 0.19 | $ | (0.25 | ) | |||||
| Discontinued operations | 0.00 | (0.03 | ) | 0.10 | (0.07 | ) | |||||||||
| Basic income (loss) per share attributable to | $ | 0.02 | $ | (0.07 | ) | $ | 0.29 | $ | (0.32 | ) | |||||
| Diluted income (loss) per share attributable to | |||||||||||||||
| Continuing operations | $ | 0.02 | $ | (0.04 | ) | $ | 0.18 | $ | (0.25 | ) | |||||
| Discontinued operations | (0.01 | ) | (0.03 | ) | 0.09 | (0.07 | ) | ||||||||
| Diluted income (loss) per share attributable to | $ | 0.01 | $ | (0.07 | ) | $ | 0.27 | $ | (0.32 | ) | |||||
Consolidated Statements of Cash Flows (In thousands of (Unaudited) | ||||||||
| 2025 | 2024 | |||||||
| Cash flows provided by (used in) operating activities: | ||||||||
| Income (loss) from continuing operations including non-controlling interests | $ | 20,988 | $ | (27,942 | ) | |||
| Adjustments to reconcile loss including non-controlling interests to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 16,379 | 16,723 | ||||||
| Amortization of deferred charges | 116 | 10 | ||||||
| Interest expense | 2,704 | 3,365 | ||||||
| Interest paid on long-term debt | (2,779 | ) | (4,203 | ) | ||||
| Unrealized foreign exchange loss | 13 | 233 | ||||||
| — | 11,939 | |||||||
| Inventory and other impairments | 217 | 10,961 | ||||||
| Non-cash lease expense | 951 | 731 | ||||||
| Share-based compensation | 1,741 | 3,747 | ||||||
| Deferred income taxes | (1,588 | ) | (1,739 | ) | ||||
| Changes in non-cash working capital items | 19,370 | (97 | ) | |||||
| Net cash provided by operating activities from continuing operations | 58,112 | 13,728 | ||||||
| Cash flows (used in) provided by investing activities: | ||||||||
| Purchases of property, plant and equipment | (18,219 | ) | (7,168 | ) | ||||
| Purchases of intangibles | (395 | ) | (158 | ) | ||||
| Equity investment | — | — | ||||||
| Repayment of note receivable | — | — | ||||||
| Net cash used in investing activities from continuing operations | (18,614 | ) | (7,326 | ) | ||||
| Cash flows (used in) provided by financing activities: | ||||||||
| Proceeds from borrowings | 27,094 | — | ||||||
| Repayments on borrowings | (34,959 | ) | (5,709 | ) | ||||
| Purchase of non-controlling interest | — | (3,817 | ) | |||||
| Proceeds from issuance of common stock and warrants | — | — | ||||||
| Issuance costs | — | — | ||||||
| Share repurchases | (2,971 | ) | — | |||||
| Proceeds from exercise of warrants and stock options | 5,031 | — | ||||||
| Other financing activities | (546 | ) | — | |||||
| Net cash used in (provided by) financing activities from continuing operations | (6,351 | ) | (9,526 | ) | ||||
| Discontinued Operations | ||||||||
| Net cash (used in) provided by operating activities from discontinued operations | (8,388 | ) | (3,381 | ) | ||||
| Net cash provided by (used in) investing activities from discontinued operations | 38,710 | (2,914 | ) | |||||
| Net cash used in financing activities from discontinued operations | (4,000 | ) | — | |||||
| Net cash flows provided by discontinued operations | 26,322 | (6,295 | ) | |||||
| Effect of exchange rate changes on cash and cash equivalents | 2,152 | (1,241 | ) | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 61,621 | (10,660 | ) | |||||
| Cash, cash equivalents and restricted cash, beginning of period | 24,631 | 35,291 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 86,252 | $ | 24,631 | ||||
| Supplemental disclosure of non-cash activities: | ||||||||
| Non-Cash - investing and financing activities | ||||||||
| Operating lease right-of-use assets | $ | 691 | $ | 117 | ||||
| Operating lease liabilities | $ | 691 | $ | 117 | ||||
| Supplemental cash flow information | ||||||||
| Income Taxes Paid | $ | 93 | $ | — | ||||
Source: